TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pediatric Endurance and Limb Strengthening (PEDALS)
Brief Summary: The study is about the effect of an exercise program using stationary bicycling for children with the spastic diplegic form of cerebral palsy. Spastic diplegia is a type of cerebral palsy that involves spasticity or "tightness" of the leg muscles. We hope to learn whether this type of exercise will allow the children to develop improved strength in the muscles that bend and straighten their knees, enhance their level of physical fitness, improve their ability to walk and improve their ability to perform other activities that are important to them. We hypothesize that children who participate in the stationary cycling intervention will gain strength in the muscles that bend and straighten their knees, will be able to complete a 600 yard walk run test (a test of endurance) more rapidly, and will improve their score on a test of function called the Gross Motor Function Measure (a test designed specifically for children with cerebral palsy).


Options:
A: Arm Label: Intervention Stationary Cycling; Type: EXPERIMENTAL; Interventions: Other: Stationary Cycling | Intervention Type: OTHER; Name: Stationary Cycling; Assigned to Arm(s): Intervention Stationary Cycling
B: Arm Label: Typically Developing Infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Program; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Arm Label: Perceptual-motor intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical therapy | Intervention Type: OTHER; Name: Physical therapy; Assigned to Arm(s): Home Program, Perceptual-motor intervention
C: Arm Label: Virtual reality video game; Type: ACTIVE_COMPARATOR; Interventions: Other: virtual reality system | Arm Label: Virtual reality system; Type: PLACEBO_COMPARATOR; Interventions: Other: virtual reality system | Intervention Type: OTHER; Name: virtual reality system; Assigned to Arm(s): Virtual reality system, Virtual reality video game
D: Arm Label: Stabilization Group; Type: EXPERIMENTAL; Interventions: Other: Core Stabilization, Other: Traditional upper extremity rehabilitation | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Traditional upper extremity rehabilitation | Intervention Type: OTHER; Name: Core Stabilization; Assigned to Arm(s): Stabilization Group | Intervention Type: OTHER; Name: Traditional upper extremity rehabilitation; Assigned to Arm(s): Control Group, Stabilization Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV-An Open-Label Prospective Study of Memantine in Institutionalized Patients With Severe Alzheimer's Disease and Significant Behavioural and Psychological Symptoms of Dementia
Brief Summary: Alzheimer's disease (AD) is the most common form of dementia and is characterized by both cognitive and behavioural symptoms ("Behavioural and Psychological Symptoms of Dementia"; BPSD). To date, there are only modestly effective treatments for BPSD, and these treatments are associated with an increased risk of mortality in elderly dementia patients. We plan to study whether treatment with medication memantine improves BPSD in severe AD patients. Thirty-two AD patients with significant BPSD, including agitation and aggression, will be treated for three months with memantine. Assessments of behavioural symptoms and global clinical outcomes will be completed after one, two and three months of treatment.


Options:
A: Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Memantine ER; Type: ACTIVE_COMPARATOR; Interventions: Drug: memantine ER | Intervention Type: DRUG; Name: memantine ER; Assigned to Arm(s): Memantine ER | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: galantamine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia
Brief Summary: The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.


Options:
A: Intervention Type: PROCEDURE; Name: hysterectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: endometrial ablation; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 3
C: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness
Brief Summary: To test the effectiveness of MNTX in advanced illness subjects.


Options:
A: Arm Label: Morphine Sulphate; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Fentanyl; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Oxycodone; Type: N/A; Interventions: Drug: methylnaltrexone | Intervention Type: DRUG; Name: methylnaltrexone; Assigned to Arm(s): Fentanyl, Morphine Sulphate, Oxycodone
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
C: Arm Label: Methylnaltrexone bromide; Type: EXPERIMENTAL; Interventions: Drug: Methylnaltrexone bromide | Intervention Type: DRUG; Name: Methylnaltrexone bromide; Assigned to Arm(s): Methylnaltrexone bromide
D: Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind Placebo-Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Chronic Opioid Therapy in Patients With Advanced Medical Illness
Brief Summary: To test the effectiveness of MNTX in advanced illness subjects.


Options:
A: Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
C: Arm Label: 'Oxycodone/Naloxone'; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Arm Label: Oxycodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone(single compound) | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): 'Oxycodone/Naloxone' | Intervention Type: DRUG; Name: Oxycodone(single compound); Assigned to Arm(s): Oxycodone
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Assessment of the Safety, Efficacy, and Practicality of an Algorithm Including Amantadine, Metformin and Zonisamide for the Prevention of Olanzapine-Associated Weight Gain in Outpatients With Schizophrenia
Brief Summary: The goal of this study is to answer the following questions:

* Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine
* Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of the changes in body that occur with weight gain
* How weight gain associated with olanzapine can affect people
* Whether treatment with amantadine, metformin or zonisamide can help eliminate weight gain associated with olanzapine and not interfere with the positive effects of olanzapine on functioning of people with schizophrenia and other diseases


Options:
A: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Liraglutide placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide Placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Liraglutide Placebo; Assigned to Arm(s): Liraglutide placebo
C: Arm Label: Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
D: Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Behavioral: Wellness education | Arm Label: Olanzapine + Amantadine; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Arm Label: Olanzapine + Metformin; Type: EXPERIMENTAL; Interventions: Drug: olanzapine, Drug: amantadine, Drug: metformin, Drug: zonisamide, Behavioral: Wellness education | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: amantadine; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: DRUG; Name: zonisamide; Assigned to Arm(s): Olanzapine + Amantadine, Olanzapine + Metformin | Intervention Type: BEHAVIORAL; Name: Wellness education; Assigned to Arm(s): Olanzapine, Olanzapine + Amantadine, Olanzapine + Metformin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Safety Evaluation of Bronchial Thermoplasty With the Alair® System in Patients With Severe Asthma
Brief Summary: The primary purpose of this study is to gather additional safety data for the subjects treated with the Alair System (hereinafter, "Alair-Treated Subjects") who previously completed the one-year study entitled: "Multicenter Randomized Clinical Trial of Bronchial Thermoplasty with the Alair System for the Treatment of Severe Asthma" (Protocol #0903-27) sponsored by Asthmatx, Inc. Subjects who elect to participate in this safety study will be followed for an additional four (4) year period beyond the PREDECESSOR STUDY'S one-year endpoint (clinicaltrials.gov number NCT00214539).


Options:
A: Arm Label: Alair Treatment; Type: N/A; Interventions: Device: Bronchial thermoplasty with the Alair System | Intervention Type: DEVICE; Name: Bronchial thermoplasty with the Alair System; Assigned to Arm(s): Alair Treatment
B: Arm Label: Alair Group; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial thermoplasty with the Alair System | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional therapy with ICS+LABA | Intervention Type: PROCEDURE; Name: Bronchial thermoplasty with the Alair System; Assigned to Arm(s): Alair Group | Intervention Type: DRUG; Name: Conventional therapy with ICS+LABA; Assigned to Arm(s): Control Group
C: Arm Label: Alair Group; Type: N/A; Interventions: Device: Bronchial Thermoplasty with the Alair System | Intervention Type: DEVICE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Alair Group
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Bronchial Thermoplasty with the Alair System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control | Intervention Type: PROCEDURE; Name: Bronchial Thermoplasty with the Alair System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Control; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone(MNTX) for the Relief of Constipation Due to Opioid Therapy in Advance Medical Illness.
Brief Summary: To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 2
B: Arm Label: Methylnaltrexone bromide; Type: EXPERIMENTAL; Interventions: Drug: Methylnaltrexone bromide | Intervention Type: DRUG; Name: Methylnaltrexone bromide; Assigned to Arm(s): Methylnaltrexone bromide
C: Arm Label: Morphine Sulphate; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Fentanyl; Type: N/A; Interventions: Drug: methylnaltrexone | Arm Label: Oxycodone; Type: N/A; Interventions: Drug: methylnaltrexone | Intervention Type: DRUG; Name: methylnaltrexone; Assigned to Arm(s): Fentanyl, Morphine Sulphate, Oxycodone
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone(MNTX) for the Relief of Constipation Due to Opioid Therapy in Advance Medical Illness.
Brief Summary: To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.


Options:
A: Arm Label: Methylnaltrexone bromide; Type: EXPERIMENTAL; Interventions: Drug: Methylnaltrexone bromide | Intervention Type: DRUG; Name: Methylnaltrexone bromide; Assigned to Arm(s): Methylnaltrexone bromide
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: SC Methylnaltrexone | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: SC Placebo | Intervention Type: DRUG; Name: SC Methylnaltrexone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: SC Placebo; Assigned to Arm(s): Arm 2
C: N/A
D: Arm Label: Targinact® (oxycodon/naloxon); Type: N/A; Interventions: Drug: Targinact® (oxycodon/naloxon) | Intervention Type: DRUG; Name: Targinact® (oxycodon/naloxon); Assigned to Arm(s): Targinact® (oxycodon/naloxon)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CONNECT Study - Clinical Evaluation Of Remote NotificatioN to rEduCe Time to Clinical Decision
Brief Summary: The purpose of this study is to determine whether the ability of clinicians to receive and review information from patients implanted with a heart device over the internet (remote care) is comparable to patients who are seen in-office for routine visits to check the status of their device.


Options:
A: Arm Label: Remote Arm; Type: EXPERIMENTAL; Interventions: Other: Remote Management | Arm Label: In-office Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: In-Office Care | Intervention Type: OTHER; Name: Remote Management; Assigned to Arm(s): Remote Arm | Intervention Type: OTHER; Name: In-Office Care; Assigned to Arm(s): In-office Arm
B: Arm Label: In-patient care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Arm Label: Telemedicine care; Type: EXPERIMENTAL; Interventions: Other: Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedicine care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): In-patient care
C: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-blind, Placebo-controlled, Dose-range-finding, Parallel-group, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of administration of linaclotide acetate in patients with chronic constipation.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 4
B: Arm Label: 72 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 145 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 290 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: 579 ug linaclotide acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: linaclotide acetate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: linaclotide acetate; Assigned to Arm(s): 145 ug linaclotide acetate, 290 ug linaclotide acetate, 579 ug linaclotide acetate, 72 ug linaclotide acetate | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): Matching Placebo
C: Arm Label: A3309 15 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: A3309 20 mg; Type: EXPERIMENTAL; Interventions: Drug: A3309 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: A3309; Assigned to Arm(s): A3309 15 mg, A3309 20 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2

Answer: B